Article

10 Important VA Studies You Might Have Missed at ASH


 

Leukemias

Survival and Treatment of Black Patients with Chronic Lymphocytic Leukemia in the Veterans Health Affairs

Black patients with chronic lymphocytic leukemia tend to have worse overall survival and an earlier age at diagnosis with higher rates of adverse cytogenetics. This retrospective analysis of VHA patients compared black and nonblack patients. It found that black patients had worse survival compared to nonblack patients in a single health care delivery system, which limits differences in access to care. Black patients were younger and had shorter periods of observation and were more frequently given first-line fludarabine.

Evaluation of Romyelocel-L Myeloid Progenitor Cells to Decrease Infections in De Novo AML Patients Receiving High-Dose Ara-C-Based Induction Therapy

Induction chemotherapy (7+3) or high-dose ara-C-based (HIDAC) for acute myeloid leukemia (AML) results in prolonged neutropenia with a high risk of serious infection and attendant morbidity, and prolonged hospitalization. Researchers, including former AVAHO president Suman Kambhampati developed a randomized, open-label, controlled Phase 2 trial to study the effect of romyelocel-L in de novo patients receiving HIDAC or 7+3 induction therapy for reduction of fever and infection. The results from pooled and 7+3 cohorts, were previously presented, showing decrease in infections and days in hospital. The results from cohorts receiving HIDAC chemotherapy are presented here. The incidence of infections was decreased during the day 15-28 period and a decrease of three days in hospital stay was observed in de novo HIDAC AML subjects receiving romyelocel-L. Romyelocel-L may provide a new option to reduce infections in AML patients undergoing HIDAC induction therapy.

Pages

Recommended Reading

STORM trial shows response in penta-refractory myeloma
Federal Practitioner
Real-world clues for optimal sequencing of CLL novel agents
Federal Practitioner
Will quad therapy become the new standard in myeloma?
Federal Practitioner
First-line bortezomib prolongs survival in MCL
Federal Practitioner
P-BCMA-101 gains FDA regenerative medicine designation
Federal Practitioner
Bortezomib may unlock resistance in WM with mutations
Federal Practitioner
FDA expands approval of brentuximab vedotin to PTCL
Federal Practitioner
FDA approves rituximab biosimilar for lymphoma
Federal Practitioner
2018: A banner year for hematology drug approvals
Federal Practitioner
CLL resistance mechanism to venetoclax identified
Federal Practitioner